Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
at 1 pa

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT07099391

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

University of Rochester Medical Center, Rochester

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06433947

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

The Tisch Cancer Institute/Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT07284758

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Perlmutter Cancer Center at NYU Langone Hospital, Brooklyn
Memorial Sloan Kettering Cancer Center, New York

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT07280013

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Research Site, New York

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06106945

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Weill Cornell Medical College, New York

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT06615479

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214, New York

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT06953960

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

MSK Commack, Commack
MSK Westchester, Harrison
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
at 2 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT05623020

Collection of Tissue Samples for Cancer Research

Roswell Park Cancer Institute, Buffalo

Nagre-recruitObservasyonal na pag-aaral

2 Months · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT00900198

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Icahn School of Medicine at Mount Sinai, New York

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT03761108

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Memorial Sloan Kettering Cancer Center Mskcc, New York

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT04973605

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT07725406

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Memorial Sloan-Kettering Cancer Center, New York

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 22, 2026 · NCT05651932

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Research Site, Great Neck
Research Site, New York
Research Site, New York
at 4 pa

Nagre-recruitPhase 3

Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Okt 21, 2026 · NCT07735637

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Mount Sinai - The Tisch Cancer Institute /ID# 272470, New York
Weill Cornell Medical College /ID# 272517, New York

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 19, 2026 · NCT06892522

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Icahn School of Medicine at Mount Sinai /ID# 277844, New York
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946, New York
Weill Cornell Medicine Myeloma Center /ID# 278216, New York

Nagre-recruitPhase 2/3

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 19, 2026 · NCT07095452

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

David H. Koch Center for Cancer Care, New York
Montefiore Medical Center PRIME, The Bronx

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 14, 2026 · NCT07648264

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
at 1 pa

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT07105059

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

New York Oncology Hematology, Albany

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT06980480

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Consent only), Harrison
Weill Cornell Medical Center (Data Analysis Only), New York
at 2 pa

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 13, 2026 · NCT07249528

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Research Site, New York
Research Site, Stony Brook

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 8, 2026 · NCT05850234

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Roswell Park Cancer Institute, Buffalo
Icahn School of Medicine at Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT06297226

Limited-duration Teclistamab

Columbia University, New York

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05932680

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity), Commack
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
Mount Sinai Hospital, New York
at 2 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06976476

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
at 1 pa

Nagre-recruit

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06055894

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All protocol activities), New York
at 1 pa

Nagre-recruitPhase 2

Edad 60 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06679829

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Site, Albany
Research Site, New York
Research Site, New York

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07391657

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

New York Oncology Hematology, Albany
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
NYU Langone Health Manhattan, New York
at 1 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07518186

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Research Site, New York

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07073547

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.